Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
- Targeting Tumor Metabolism in Papillary Kidney Cancers
(Posted: 12/14/2010) - In this trial, patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cancer that has spread beyond the kidneys will be treated with erlotinib and bevacizumab.
- Combination Therapy for Advanced Kaposi Sarcoma
(Posted: 11/16/2010) - In this clinical trial, adult patients with any form of advanced Kaposi sarcoma will be treated with liposomal doxorubicin and bevacizumab every 3 weeks for a maximum of six treatments. Patients who respond to this therapy or have stable disease will receive bevacizumab alone every 3 weeks for a maximum of 11 treatments.
- Targeted Antibody Therapy for Metastatic Adrenocortical Carcinoma
(Posted: 11/02/2010) - In this clinical trial, 20 patients with recurrent, metastatic, or otherwise unresectable adrenocortical carcinoma who have not been previously treated with systemic therapies will receive IMC-A12 and mitotane to determine the safety of the combined therapy. If the combination is safe, an additional 102 patients will be randomly assigned to receive the combined treatment or mitotane alone.
- Tailored Treatment for Breast Cancer
(Posted: 05/23/2006, Updated: 10/22/2010) - In this trial, doctors will use a test called the Oncotype DX Breast Cancer Assay, which measures the activity of a set of genes in breast tumor tissue, to determine which women will receive adjuvant chemotherapy in addition to hormone therapy.
- Eliminating Hairy Cell Leukemia Minimal Residual Disease
(Posted: 10/19/2010) - In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment, and who have not been treated or have had only one prior treatment with cladribine, will be randomly assigned to receive cladribine with either concurrent rituximab or rituximab at least 6 months after completing cladribine therapy.